Active Biotech…announced that the ﬁrst patient has been dosed in the Phase Ib/II clinical study of tasquinimod following an amendment to the study protocol, with increased flexibility in the dosing regimen of tasquinimod.

tasquinimod (ABR-215050) - Active Biotech

Jul 24, 2026